Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Vascular smooth muscle contraction | R-HSA-445355 | map04270 | metampicillin | 6713928 | drug-path |
ABC transporters | R-HSA-1369007 | map02010 | metampicillin | 6713928 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | nifenazone | 4487 | drug-path |
Antigen processing and presentation | R-HSA-1236975 | map04612 | nifenazone | 4487 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | nifenazone | 4487 | drug-path |
Apoptosis | R-HSA-109581 | map04210 | nifenazone | 4487 | drug-path |
Asthma | R-HSA-444620 | map05310 | nifenazone | 4487 | drug-path |
Parkinson's disease | R-HSA-1643685 | 0 | nifenazone | 4487 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | nifenazone | 4487 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | nifenazone | 4487 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | nifenazone | 4487 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | nifenazone | 4487 | drug-path |
Chronic myeloid leukemia | R-HSA-9680350 | map05220 | nifenazone | 4487 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | ethosuximide | 3291 | drug-path |
ECM-receptor interaction | R-HSA-373711 | map04512 | ethosuximide | 3291 | drug-path |
Gap junction | R-HSA-190861 | map04540 | ethosuximide | 3291 | drug-path |
Notch signaling pathway | R-HSA-157118 | map04330 | ethosuximide | 3291 | drug-path |
RNA polymerase | R-HSA-73864 | map03020 | ethosuximide | 3291 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | chlorphenesin | 8569 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | chlorphenesin | 8569 | drug-path |